Skip to main content

Table 4 Odds ratios (ORs) for disease development in pre-symptomatic individuals for different ACPA and anti-CCP2 in combination with smoking and HLA-SE compared with individuals being ACPA/anti-CCP2 negative, HLA-SE negative, and non-smokers as reference

From: Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis

Anti-CCP2/ACPA Smoking HLA-SE Cases/controls OR (95% CI)
(n = 348) (n = 366) n/n
Anti-CCP2    345/552a  
31/172 Ref
+ 10/1 55.48 (6.86–448.99)
+ 52/160 1.80 (1.10–2.96)
+ 52/121 2.38 (1.44–3.94)
+ + 26/3 48.09 (13.71–168.64)
+ + 84/86 5.42 (3.33–8.82)
+ + 24/4 33.29 (10.80–102.59)
+ + + 66/5 73.24 (27.32–196.37)
Anti-CEP-1/Eno5-21    345/541a  
33/163 Ref
+ 8/7 5.65 (1.92–16.64)
+ 58/147 1.95 (1.20–3.16)
+ 56/117 2.36 (1.45–3.86)
+ + 20/14 7.05 (3.24–15.37)
+ + 96/79 6.00 (3.72–9.68)
+ + 20/7 14.11 (5.52–36.08)
+ + + 54/7 38.10 (15.94–91.11)
Anti-Fibβ36-52    345/541a  
31/161 Ref
+ 10/9 5.77 (2.17–15.36)
+ 56/149 1.95 (1.19–3.19)
+ 54/117 2.40 (1.45–3.96)
+ + 22/12 9.52 (4.27–21.22)
+ + 97/79 6.38 (3.92–10.37)
+ + 22/7 16.32 (6.42–41.51)
+ + + 53/7 39.32 (16.36–94.51)
Anti-CCP-1/Fil307-324    345/541a  
33/168 Ref
+ 8/2 20.36 (4.14–100.24)
+ 60/157 1.95 (1.21–3.14)
+ 52/120 2.21 (1.35–3.62)
+ + 18/4 22.91 (7.28–72.05)
+ + 104/80 6.62 (4.12–10.63)
+ + 24/4 30.55 (9.94–93.84)
+ + + 46/6 39.03 (15.42–98.82)
Anti-CEP-1/Eno5-21 + anti-Fibβ36-52 + anti-CCP-1/Fil307-324 b 345/541a
39/170 Ref
+ 1/0
+ 72/159 1.97 (1.26–3.08)
+ 66/123 2.33 (1.48–3.70)
+ + 6/1 26.15 (3.06–223.50)
+ + 122/85 6.26 (4.01)
+ + 11/1 47.95 (6.01–382.46)
+ + + 28/2 61.03 (13.95–267.05)
Anti-CEP-1/Eno5-21 + anti-Fibβ36-52 + anti-CCP-1/Fil307-324 + anti-CCP2 c 204/464a  
20/151 Ref
+ 1/0
+ 37/133 2.10 (1.16–3.80)
+ 37/105 2.66 (1.46–4.84)
+ + 5/0
+ + 65/72 6.82 (3.84–12.11)
+ + 11/1 83.05 (10.17–677.91)
+ + + 28/2 105.70 (23.39–477.74)
  1. aTotal number included in analysis. bPositive = positive for all of the three antibodies and negative = any of the antibodies negative. cPositive = all four antibodies positive and negative = all four antibodies negative. anti-CCP2=anti-cyclic citrullinated peptide antibodies, ACPA= anti citrullinated peptide/protein antibodies, HLA-SE= HLA shared epitope, OR= odds ratio, CI= confidence intervals, anti CEP-1/Eno5-21= antibodies against alpha-Enolase, anti-citC1359-369= antibodies against collagen type II aa 359-369 with two citrulline residues, anti- Fibα580-600=antibodies against fibrinogen (Fib) Fibα580-600, anti-Fibα561-583= antibodies against Fibα561-583, anti- Fibβ62-81a(72)=antibodies against Fibβ62-81a(72), anti-Fibβ62-81b(74)= antibodies against Fibβ62-81b(74), anti-Fibβ36-52= antibodies against Fibβ36-52, anti- CCP-1/Fil307-324= antibodies against filaggrin, anti- Vim60-75= antibodies against vimentin (Vim)60-75, anti-Vim2-17= antibodies against Vim 2-17.